StockData
Innoviva, Inc. logo

Innoviva, Inc. (INVA) company profile

INVANasdaqPharmaceutical PreparationsFiscal year ends December 31
Số liệu tài chính tới Q3 năm tài chính 2026, quý kết thúc ngày Sep 30, 2026Last filing: 10-Q on Nov 4, 2026Score 14/3039% below fair value
$18.30−0.19 (-1.03%)

Close on Nov 17, 2026Market cap $1.32BP/E 9.3Yield –

About Innoviva

Pharmaceutical Preparations, SIC 2834

Innoviva, Inc. is a biopharmaceutical company that manages a portfolio of royalty-bearing medicines, critical care therapies, and healthcare assets. Its business focuses on two primary areas: commercializing specialty treatments and licensing respiratory medications. The company’s partnered portfolio includes respiratory drugs RELVAR/BREO ELLIPTA and ANORO ELLIPTA. Through its critical care and infectious disease platform, Innoviva provides hospital-focused therapies such as GIAPREZA for distributive shock, XACDURO for bacterial pneumonia, XERAVA for intra-abdominal infections, ZEVTERA for severe bacterial conditions, and NUZOLVENCE for gonorrhea. These products serve healthcare institutions, medical professionals, and patients being treated for acute infections, respiratory conditions, and critical illnesses.

The company is headquartered in Burlingame, California. Its commercial operations and approved pharmaceuticals span international markets, including the United States, Europe, the United Kingdom, and several Asian jurisdictions such as China, Hong Kong, Singapore, and Taiwan. Innoviva distributes its therapies through wholly owned subsidiaries as well as regional commercial partners across North America, Europe, and the Asia-Pacific region.

Summary of the business section of Innoviva's latest annual report, written by StockData.

Company profile

Company

Legal name
Innoviva, Inc.
Founded
1996
Headquarters
Burlingame, CA
Address
1350 Old Bayshore Highway, Suite 400 94010
Phone
(650) 238-9600
Employees
159, Dec 31, 2025
Industry
Pharmaceutical Preparations
Incorporated in
Delaware
Fiscal year ends
December 31
Auditor
Deloitte & Touche LLP, San Jose, CA

Stock & identifiers

Ticker
INVA
Exchange
Nasdaq
IPO date
Oct 5, 2004
Shares outstanding
72M, Jul 31, 2026
Public float
$1.26B, Jun 30, 2025
Filer category
Large accelerated filer
SEC CIK
1080014
CUSIP
45781M101
ISIN
US45781M1018
FIGI
BBG000CG9XT7
Share class FIGI
BBG001SF23V0
LEI
549300ACOX4QTBES6535
EIN
94-3265960

Executives and directors

Officers and directors who filed ownership reports (Forms 3, 4, 5) in the last two years

NamePositionShares owned
Pavel RaifeldChief Executive Officer, Director284,799
Stephen BassoChief Financial Officer88,013
Marianne ZhenChief Accounting Officer56,389
Josephine LindenDirector15,194
Derek A. SmallDirector45,035
Sarah J. SchlesingerDirector140,492
Mark DiPaoloDirector140,492
Jules HaimovitzDirector152,692

CEO pay and shareholder return

Pay versus performance table from the proxy statement

Fiscal yearCEO total payCEO pay actually paidOther executives (avg)Value of $100 investedPeer group
FY2025$5.40M$6.12M$1.63M$161$116
FY2024$2.72M$3.09M$1.02M$140$88
FY2023$868.65K$1.06M$1.13M$129$94
FY2022$1.80M$7.13K$665.25K$107$90
FY2021$1.27M$1.25M$614.26K$139$100
FY2020$716.24K$489.27K$558.87K$88$126

“Actually paid” adjusts reported pay for changes in the value of equity awards. Shareholder return assumes $100 invested at the start of the measurement period, as disclosed by the company.

Executive compensation, fiscal 2025

Summary compensation table from the latest proxy statement

ExecutiveSalaryBonusStock awardsOption awardsOtherTotalvs. prior year
Pavel Raifeld
Chief Executive Officer
$600.00K$378.00K$2.65M$1.75M$23.33K$5.40M+99%
Stephen Basso
Chief Financial Officer and President of IST
$475.00K$223.49K$691.09K$765.35K$18.35K$2.17M+115%
Marianne Zhen
Chief Accounting Officer
$420.00K$245.44K$161.60K$229.99K$25.83K$1.08M+12%

Stock and option awards are grant-date fair values, not realized pay. “Other” includes pension value changes and all other compensation. Source proxy statement.

Employees

Headcount reported in annual reports

“As of December 31, 2025, we had 159 employees, all of whom were full-time employees.”

Corporate history

Events identified from SEC filings

DateEventDetails
Aug 7, 2023Listing noticeNotice of delisting or failure to satisfy a listing rule (8-K Item 3.01)
Oct 28, 2022Acquisition / saleCompletion of acquisition or disposition of assets (8-K Item 2.01)
Aug 22, 2022Acquisition / saleCompletion of acquisition or disposition of assets (8-K Item 2.01)
Jul 25, 2022Tender offerThird-party tender offer for the company's shares
Jul 11, 2022Acquisition / saleCompletion of acquisition or disposition of assets (8-K Item 2.01)
Jun 7, 2022Tender offerThird-party tender offer for the company's shares
Mar 25, 2022Auditor changeChange in certifying accountant (8-K Item 4.01)
Feb 28, 2019Auditor changeChange in certifying accountant (8-K Item 4.01)
Dec 7, 2015Name changeName changed from THERAVANCE INC to Innoviva, Inc.
Jun 5, 2014Acquisition / saleCompletion of acquisition or disposition of assets (8-K Item 2.01)
Aug 1, 2007Tender offerThird-party tender offer for the company's shares
Oct 5, 2004IPOInitial public offering priced (424B4 prospectus)
Aug 2, 2000Name changeName changed from ADVANCED MEDICINE INC to THERAVANCE INC

See a number that looks wrong?